Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with stem cell rescue for small-cell lung cancer: Brief report on the results of a phase-I/II trial

Oncology

Volumn 63, Issue 3, 2002, Pages 248-253

  Oelmann, E ^a   Thomas, M ^a   Serve, H ^a   Kienast, J ^a   Zuhlsdorf M ^a   Mohr, M ^a   Klinke, F ^c   Dolken G ^b   Macha, H ^c   Schmidt, E W ^d   Berdel, Wolfgang E ^a,e  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b University Hospital   (Germany)

^c Kliniken   (Germany)

^d Klinikum   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Small cell lung cancer; Stem cell rescue; Tandem high dose therapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION; LEUKAPHERESIS; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MONONUCLEAR CELL; NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; CARBOPLATIN; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELLS; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 0036972013     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065473     Document Type: Article

References (16)

1. Smyth JF, Fowlie SM, Gregor A, Crompton GK, Busuttil A, Leonard RC, Grant IW: The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med 1986;61:969-976.
2. Clark R, Ihde DC: Small-cell lung cancer: Treatment progress and prospects. Oncology (Huntingt.) 1998;12:647-658.
3. Sandler AB: Current management of small cell lung cancer. Semin Oncol 1997;24:463-476.
4. Elias A: Dose-intensive therapy in lung cancer. Cancer Chemother Pharmacol 1997;40 (suppl):64-69.
5. Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser E-D, Thiel E, Zwingers T, Berdel WE: Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer. Oncology 1997;54:363-370.
6. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ, for the Medical Research Council Lung Cancer Working Party: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council multicenter randomized trial. J Clin Oncol 2000;18:395-404.
7. Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J: Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients. J Clin Oncol 1998;16:642-650.
8. Pujol J-L, Douillard J-Y, Riviere A, Quoix E, Lagrange J-L, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T: Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: A multi-center randomized phase III study. J Clin Oncol 1997;15:2082-2089.
9. Trillet-Lenoir V, Green JA, Manegold C, von Pawel J, Gatzemeier U, Lebau B, Depierre A, Johnson P, Decoster G, Matcham J, Ewen C: Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: A long-term follow-up. Eur J Cancer 1995;31A: 2115-2116.
10. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R: Chemo-radiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632-1641.
11. Elias AE, Cohen BF: Dose-intensive therapy in lung cancer; in Armitage JO, Antman KH (eds): High-Dose Cancer Therapy, ed 2. Baltimore, Williams & Wilkins, 1995, pp 824-846.
12. Humblet Y, Symann M, Bosly A, Delaunois L, Francis C, Machiels J, Beauduin M, Doyen C, Weynants P, Longueville J, Prignot J: Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study. J Clin Oncol 1987;5:1864-1873.
13. Arriagada R, Le Chevalier T, Pignon J-P, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffie P: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329: 1848-1852.
14. Hornung RL, Longo DL: Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 1992;80:77-83.
15. Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquée L, Pasini F, Marangolo M: Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999;17:3531-3539.
16. Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG: Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995;13:148-156.